Robert R. Orr
Distinguished in Emphysema

Dr. Robert R. Orr

Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine
6677 W Thunderbird Rd, Suite E, 
Glendale, AZ 
Accepting New Patients
Offers Telehealth
Distinguished in Emphysema
6677 W Thunderbird Rd, Suite E, 
Glendale, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Robert Orr is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Glendale, Arizona. Dr. Orr is rated as a Distinguished provider by MediFind in the treatment of Emphysema. His top areas of expertise are Emphysema, Bullae, Pleural Effusion, and Obstructive Sleep Apnea. Dr. Orr is currently accepting new patients.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pulmonary Medicine
Intensive Care Medicine
Sleep Medicine
Licenses
Critical Care Medicine in AZ
Hospital Affiliations
Banner Boswell Medical Center
Languages Spoken
English
Farsi
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EMI Health
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Highmark
  • EPO
  • HMO
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MercyCare
  • EPO
  • HMO
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VibrantRx
  • MEDICARE PDP
  • OTHER MEDICARE
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

PHOENIX MEDICAL GROUP PC
6677 W Thunderbird Rd, Suite E, Glendale, AZ 85306
Other Locations
PHOENIX MEDICAL GROUP PC
9171 W Thunderbird Rd, Suite 101, Peoria, AZ 85381

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy
A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drug: SUVN-G3031
Study Phase: Phase 2
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks (With a 48-week Safety Subset) in Subjects With Moderate to Severe COPD
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks (With a 48-week Safety Subset) in Subjects With Moderate to Severe COPD
Enrollment Status: Completed
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Ensifentrine
Study Phase: Phase 3
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety & Tolerability, and PK of INS1007 Administered Once Daily for 24 Weeks in Subjects With Non-CF Bronchiectasis - The Willow Study
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety & Tolerability, and PK of INS1007 Administered Once Daily for 24 Weeks in Subjects With Non-CF Bronchiectasis - The Willow Study
Enrollment Status: Completed
Publish Date: March 27, 2023
Intervention Type: Drug
Study Phase: Phase 2
Randomized, Double-blind, Placebo-controlled, Multiple-Dose, Study to Assess the Safety, Tolerability, PK and PD After 4 Weeks of Once Weekly Sc. Inj. of PB1046 in Adults With Stable HFrEF, and in Subjects With Cardiac Dysfunction Secondary to DMD
Randomized, Double-blind, Placebo-controlled, Multiple-Dose, Study to Assess the Safety, Tolerability, PK and PD After 4 Weeks of Once Weekly Sc. Inj. of PB1046 in Adults With Stable HFrEF, and in Subjects With Cardiac Dysfunction Secondary to DMD
Enrollment Status: Completed
Publish Date: July 14, 2022
Intervention Type: Drug
Study Phase: Phase 2
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Enrollment Status: Completed
Publish Date: February 15, 2021
Intervention Type: Other
2016-11: Blood Sample Collection in Subjects Participating in a Lung Cancer Screening Program
2016-11: Blood Sample Collection in Subjects Participating in a Lung Cancer Screening Program
Enrollment Status: Completed
Publish Date: February 15, 2021
Intervention Type: Other
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Velusetrag for the Treatment of Diabetic or Idiopathic Gastroparesis
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Velusetrag for the Treatment of Diabetic or Idiopathic Gastroparesis
Enrollment Status: Completed
Publish Date: April 17, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

3 Total Publications

Performance of the microINR Point-of-Care System Used by Self-Testing Patients: A Multicenter Clinical Trial.
Performance of the microINR Point-of-Care System Used by Self-Testing Patients: A Multicenter Clinical Trial.
Journal: TH open : companion journal to thrombosis and haemostasis
Published: June 21, 2021
Similar Doctors
Distinguished in Emphysema
Dr. Craig M. Rundbaken
Pulmonary Medicine
Distinguished in Emphysema
Dr. Craig M. Rundbaken
Pulmonary Medicine

Craig M Rundbaken Do PLLC

14300 W Granite Valley Dr, Suite E23, 
Sun City West, AZ 
 (10.4 miles away)
623-975-0500
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Craig Rundbaken is a Pulmonary Medicine provider in Sun City West, Arizona. Dr. Rundbaken is rated as a Distinguished provider by MediFind in the treatment of Emphysema. His top areas of expertise are Coccidioidomycosis, Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, Lung Nodules, and Advanced Bronchoscopy. Dr. Rundbaken is currently accepting new patients.

Distinguished in Emphysema
Dr. Mahmoud A. Mahafzah
Pulmonary Medicine | Intensive Care Medicine
Distinguished in Emphysema
Dr. Mahmoud A. Mahafzah
Pulmonary Medicine | Intensive Care Medicine

Banner Hospital Based Physicians Arizona LLC

1400 S Dobson Rd, 
Mesa, AZ 
 (24.2 miles away)
480-412-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mahmoud Mahafzah is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Mesa, Arizona. Dr. Mahafzah is rated as a Distinguished provider by MediFind in the treatment of Emphysema. His top areas of expertise are Emphysema, Bullae, ALK-Positive Non-Small Cell Lung Cancer, and Small Cell Lung Cancer (SCLC). Dr. Mahafzah is currently accepting new patients.

Distinguished in Emphysema
Dr. Abdullah M. Yonan
Pulmonary Medicine
Distinguished in Emphysema
Dr. Abdullah M. Yonan
Pulmonary Medicine

Phoenix Medical Group PC

6677 W Thunderbird Rd, Suite E, 
Glendale, AZ 
 (0.1 miles away)
623-815-7800
Languages Spoken:
English, Arabic, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Abdullah Yonan is a Pulmonary Medicine provider in Glendale, Arizona. Dr. Yonan is rated as a Distinguished provider by MediFind in the treatment of Emphysema. His top areas of expertise are Hospital-Acquired Pneumonia, Atypical Pneumonia, Emphysema, Gastrostomy, and Endoscopy. Dr. Yonan is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Orr's expertise for a condition
ConditionClose
    View All 33 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile